RecruitingNot ApplicableNCT05553652

The Effect of ASTARTE™ on Recurrent Urinary Tract Infection

The Effect of ASTARTE™; Lactobacillus Crispatus, Lactobacillus Rhamnosus, Lactobacillus Jenesii and Lactobacillus Gasseri on the Reduction of Risk Factors for Recurrent Urinary Tract Infection in Women

Sponsor

Hvidovre University Hospital

Enrollment

720 participants

Start Date

Sep 19, 2022

Study Type

INTERVENTIONAL

Conditions

recurrent urinary tract infection

Summary

Investigate the effect of dietary supplements/probiotic ASTARTE™ ( L. crispatus, L. rhamnosus, L. jensenii, L. gasseri) on the microbiome composition in the intestine and vagina and thereby a reduction of risk factors for the development of rUTI during 6 months of intervention in women aged 18-40 years. This is measured by the incidence of symptomatic UTI.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying ASTARTE™ oral capsules and Placebo oral capsules for people with recurrent urinary tract infection. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 40 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.